Name: The BALATON/COMINO Trials: Study Overview and Week 24 Results
Uploaded: 2024-10-23T00:00:00.0000000
Duration: T00H02M45S
Description: The BALATON/COMINO Trials: Study Overview and Week 24 Results

Name: The BALATON/COMINO Trials: Study Overview and Week 24 Results

Description: The BALATON/COMINO Trials: Study Overview and Week 24 Results

Thumbnail URL: https://cadmoremediastorage.blob.core.windows.net/9f5cb00c-2908-4ce3-9edc-6625eca7e796/videoscrubberimages/Scrubber_6.jpg

Duration: T00H02M45S

Embed URL: https://stream.cadmore.media/player/9f5cb00c-2908-4ce3-9edc-6625eca7e796

Content URL: https://cadmoreoriginalmedia.blob.core.windows.net/9f5cb00c-2908-4ce3-9edc-6625eca7e796/02_RVO Balaton_Comino_09Oct24.mp4?sv=2019-02-02&sr=c&sig=rE8Bx0jor03iAE0vZPSTufQvmQDTESzXeJloPjQNYPs%3D&st=2024-11-21T09%3A11%3A34Z&se=2024-11-21T11%3A16%3A34Z&sp=r

Upload Date: 2024-10-23T00:00:00.0000000

Transcript: Language: EN.
Segment:1 Introduction.
[MUSIC PLAYING] Retinal vein occlusion, or RVO, is a retinal vascular disorder which stops blood flow to the retina. The backlog of blood flow results in a buildup of pressure within the vein, which eventually leads to bleeding into the retina. The three main types of RVO are classified by the specific vein that is affected.
VEGF-A and Ang-2 are implicated in the pathogenesis of RVO. Faricimab is the first bispecific antibody targeting both of these pathways.
Segment:2 Study Design.
SPEAKER: BALATON and COMINO are phase III studies that evaluated the efficacy and safety of faricimab in comparison to aflibercept, an anti-VEGF-A agent, in patients with macular edema secondary to branch RVO, and central or hemi-retinal RVO respectively. Patients were randomized in a double-masked fashion to receive either faricimab or aflibercept up to week 24. From week 24 to week 72, all patients received faricimab according to a modified treat-and-extend dosing regimen.
Segment:3 Results.
SPEAKER: At week 24, patients in both treatment arms achieved rapid and robust vision gains, with faricimab demonstrating non-inferiority compared with aflibercept, as well as rapid and robust reductions in central subfield thickness. At week 24, more patients treated with faricimab achieved an absence of macular leakage compared to those treated with aflibercept.
SPEAKER: Approximately 20% to 25% of patients in each arm experienced ocular adverse events, which were mostly mild or moderate in severity. Overall, faricimab was well-tolerated, with a safety profile comparable to aflibercept.
Segment:4 Conclusions.
SPEAKER: Faricimab, via dual inhibition of Ang-2 and VEGF-A, offers disease control for patients with RVO. Patients achieved rapid and sustained BCVA gains and CST reductions through week 24, with more patients treated with faricimab demonstrating an absence of macular leakage at week 24. BALATON and COMINO results to week 72 may provide insights into the potential long-term benefits of a modified faricimab treat-and-extend regimen on reducing treatment burden in patients with RVO.
Segment:5 Disclosures and Closing.
SPEAKER: [MUSIC PLAYING]

Cadmore media player playing video The BALATON/COMINO Trials: Study Overview and Week 24 Results

Video Player

Transcript

Segments

End of Video Player Control